External link for 82VS
Boston, MA, US
82VS reposted this
We’re excited to invite you to our second annual R&D Day on Tuesday, March 25, 2025 at MassBio in Cambridge, MA! This year, we’ll showcase groundbreaking advancements in antibody discovery, cell therapy, and genetic medicines, along with insights from select partners who are driving innovation forward. Learn more and register here 👉 https://lnkd.in/e74BbGgW #maythebestdrugwin #makemedicinetogether #DrugDiscovery #Innovation #AlloyRNDDay
Congratulations to the Ypsilon Therapeutics team! This significant achievement will accelerate their mission in advancing innovative cancer therapies. We are proud to support their progress and are excited to see the continued impact in the fight against cancer.
🎉 Exciting News for Ypsilon and 82VS! 🎉 Ypsilon Therapeutics has been awarded a $2.7M grant to advance its TCRm antibody program, bringing next-gen medicines to patients with hard-to-treat cancers. This funding will help accelerate Ypsilon’s lead therapeutic toward drug candidate nomination and supports its expansion to Texas, strengthening the state’s biotech ecosystem. Congrats to Dongxing Zha and the team at 82VS! Read the full press release here 👉 https://lnkd.in/e-mHXC8Z #TCRm #CPRIT #YpsilonTherapeutics #maythebestdrugwin #makemedicinetogether
82VS reposted this
I am thrilled we at 82VS are partnering with CMT Research Foundation on this innovative approach to make medicines for Charcot-Marie-Tooth disease. CMT is the most common rare peripheral neuropathy with no FDA approved treatments to date. We are excited to work with CMTRF and leaders in the CMT field to make better CMT medicines. Thank you the the CMT Research Foundation team for their leadership and vision to creatively partner and support development of life-changing medicines for CMT. #makemedicinestogether #CMTResearch
CMTRF is pleased to announce that we have invested over $500,000 in a program led by 82VS, the venture studio of Alloy Therapeutics, Inc. to discover and develop novel Antibody Oligonucleotide Conjugate therapeutics for CMT. Oligonucleotide therapeutics offer promise for treating genetic disorders but have faced challenges as potential drugs for CMT due to limited delivery to the peripheral nerves and affected cell types. Transferrin receptor (TfR1) antibodies have recently been shown to enhance oligonucleotide delivery to muscle, brain and peripheral nerves. This project by 82VS aims to combine Alloy Therapeutics' novel TfR1 antibodies with oligonucleotides to improve delivery and efficacy in CMT-relevant tissues. If successful, this approach could enable treatments for all types of CMT. Read more here: https://lnkd.in/gbA9tD7p
82VS reposted this
Supporting early stage biotech is in our DNA! We've invested in 8 innovative young companies through the 2022 and 2023 Platinum Program and together with our pharma, services, and lab partners around the world we are collectively supporting their launch and growth. Learn more about our growing portfolio of Platinum Ticket investments. And stay tuned for the 2025 Platinum Program launch in the new year! Alloy Therapeutics, Inc., Goodwin, van den Boom & Associates LLC Eli Lilly and Company, Ono Venture Investment
Exciting times at 82VS, as we gear up and head to Arlington, Texas this week to attend and sponsor BioNTX! This event is a fantastic opportunity to connect with investors, entrepreneurs, scientists, and other professionals dedicated to advancing the biotech industry. If you're in North Texas, swing by the summit on Thursday to meet the team and to see - Errik Anderson, Managing Partner 82VS & CEO and Founder of Alloy Therapeutics, discuss “The Role of Philanthropy in Global Health, Building Biotech Ecosystems and Driving Innovation” from 12:15pm to 1:15pm - Victor Stone M.D. (石井 喜英), General Partner 82VS & Head of Cell Therapies Alloy Therapeutics moderate a session for Entrepreneurs on "Navigating Innovation and Growth" from 3:25pm to 4:05pm Also, stop at our booth to learn more about our Dallas-based Biotech Startup Academy (BSA) and explore NewCo funding opportunities. #makemedicinetogether Looking forward to meeting everyone! #BioNTX #Biotech #Innovation #82vs https://lnkd.in/d2aAe2iJ
Aakha Biologics, is hiring! Aakha Biologics is building best-in-class antibody-based assets to redirect immune cells and tackle cancers that escape immune surveillance. This role presents an opportunity to learn from an exceptional founder, Hemanta Baruah. For more information on the role and Aakha, please visit our job board here: https://lnkd.in/edses2CZ
We are thrilled to announce that Ypsilon Therapeutics has been selected as a finalist for the Life Sciences Innovation Summit 2024, organized by J.P. Morgan Asset Management's Life Sciences Private Capital, Blue Horizon Advisors, and United AlSaqer Group. Being named a finalist is a testament to the hard work and dedication of our team. We look forward to presenting at the summit and connecting with industry leaders and investors! https://lnkd.in/ejdu7fnT